Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-04-19 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-19 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the company's fourth board meeting, including approvals of various reports and proposals such as the 2023 annual report, financial statements, profit distribution plan, internal control report, and other governance-related matters. It references that the actual reports are published separately on the official information disclosure website (cninfo.com.cn) and provides links or announcement numbers for those reports. The document itself does not contain the full financial data or the reports but is a formal announcement of the board meeting decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or approvals. The document length is 3332 characters, relatively short and focused on meeting resolutions rather than full reports. Therefore, the correct classification is MANG with high confidence.
2024-04-19 Chinese
赛隆药业2024年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 first extraordinary general meeting (EGM) of shareholders of a company. It details the legality and validity of the meeting's convening, attendance, voting procedures, and results. The document includes specific voting outcomes for the election of board members and amendments to the company bylaws. It does not contain financial statements or management discussion of financial results, nor is it a report publication announcement. The content is focused on the verification and certification of the shareholder meeting process and results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 6000 characters, so it is not a brief announcement but a full legal opinion on the voting results. Therefore, the appropriate classification is DVA.
2024-04-07 Chinese
第四届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the fourth Supervisory Board of Sailong Pharmaceutical Group Co., Ltd. It details the election of the chairman of the Supervisory Board and confirms the meeting's compliance with legal and regulatory requirements. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, and no investor presentation content. The document is a corporate governance announcement related to board activities but specifically about the Supervisory Board meeting resolutions, which fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct announcement of board meeting resolutions.
2024-04-07 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the first meeting of the fourth board of directors of the company. It details the election of the board chairman, appointment of board committees, and hiring of senior management and internal audit personnel. It includes voting results and references to other announcements for further details. There are no financial statements or detailed financial data presented. The document is clearly about board and management changes and appointments, which fits the category of Board/Management Information (MANG). The document length is short and it is an announcement, not a full report or detailed presentation.
2024-04-07 Chinese
关于聘任公司内部审计负责人及证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of the company's internal audit head and securities affairs representative. It includes details about the qualifications and backgrounds of the appointed individuals. There is no financial data, no report attached or referenced as being published, and no mention of voting results or shareholder meetings. The content focuses on management appointments, specifically internal audit and securities affairs roles, which falls under changes in senior management or board-related personnel. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear appointment details and absence of other report types.
2024-04-07 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.